Evaluating Effect of Low-Sodium and Regular Diets on Heart Failure Outcomes
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Maya Guglin, MD
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Length of hospital stay
Overview
Brief Summary
The purpose of this study is to understand if low sodium (cardiac) diet is indeed necessary for better health outcomes in patients who suffered heart failure. This study will investigate the association between sodium intake and risk for 30-day re-admission in Heart Failure (HF) patients.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Above 18 years of age
- •Hospitalization due to Heart Failure admitted within 24 hours
Exclusion Criteria
- •Concomitant hypertension (blood pressure \>150/90 mmHg on admission)
- •End stage renal disease (on hemodialysis or peritoneal dialysis
- •Cardiogenic shock
Arms & Interventions
Normal Salt Diet
3-4 gm/day salt diet
Intervention: Normal Salt Diet (Other)
Cardiac Diet
2 gm/day salt diet
Intervention: Cardiac Diet (Other)
Outcomes
Primary Outcomes
Length of hospital stay
Time Frame: Hospital admission to time of discharge assessed up to 1 year
number of days the patient remains hospitalized
30-day readmission
Time Frame: 30 days after discharge from hospital after index event
readmission to hospital within 30 days of discharge from the index event
NT-proBNP on discharge
Time Frame: time of hospital admission to 30 days after discharge
Measurement of blood levels of NT-ProBNP a biomarker for diagnosing and assessing the severity of heart failure.
Loop diuretic requirement during index admission
Time Frame: time of hospital admission to 30 days after discharge
Furosemide, torsemide, and bumetanide are specific loop diuretics used in the treatment of fluid overload / retention conditions like congestive heart failure.
Secondary Outcomes
No secondary outcomes reported
Investigators
Maya Guglin, MD
Section Chief, Heart Failure/Transplant/MCS at Rutgers Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey